Buy & Sell Gilead Sciences, Inc. (GILD) – Gilead Sciences, Inc. Price Today
Aura AI Summary
Key Stats
- $168.64BMarket Cap
- HealthSector
- -13.83%3M Drawdown
- $183.97BEnterprise Value
- 2.41%Dividend Yield
- 57% Buy | 43% SellTrading Activity
- 89 daysTypical Hold Time
Gilead Sciences, Inc. (GILD) is currently valued at a market capitalization of $168.64B, with an enterprise value of $183.97B. Over the past 52 weeks, Gilead Sciences, Inc. has traded between a low of $96.91 and a high of $155.8, highlighting its annual price range. Over the past three months, Gilead Sciences, Inc. has recorded a drawdown of -13.83%, reflecting recent price volatility. Gilead Sciences, Inc. offers a dividend yield of 2.41%, with the most recent dividend of $0.82 paid on 13 Mar 26. On average, investors hold Gilead Sciences, Inc. for approximately 89 days, indicating typical investor behavior on the platform.
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
